

Persistent Thrombocytopenia Post Autologous Transplant In A Case Of Extra Nodal Nk Cell Lymphoma


Goel D¹, Langer S^{2*}, Kotwal J³, Saraf A⁴, Prakhar P⁵



DOI:<https://doi.org/10.17511/jopm.2024.i02.03>

- ¹ Deepak Goel, Senior Resident, Department of Haematology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India.
^{2*} Sabina Langer, Senior Consultant, Department of Laboratory Haematology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India.
³ Jyoti Kotwal, Consultant, Department of Haematology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India.
⁴ Amrita Saraf, Senior Consultant, Department of Haematology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India.
⁵ Pallavi Prakhar, Associate Consultant, Department of Haematology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India.

Natural killer (NK)-cell lymphomas are a rare type of lymphoid malignancy with predominantly extranodal nasal involvement leading to destruction of midline head and neck structures. This article presents a case of extranodal nasal type NK cell lymphoma which even after aggressive treatment relapsed in leukemic form with no evidence of lesion at the primary site or any solid organ. This case report aims to highlight the importance of careful peripheral smear examination, knowledge of flow cytometry in early and accurate diagnosis of leukemic spillover of this rare entity and the need for aggressive treatment.

Keywords: NK/T-cell non-Hodgkin lymphoma, Aggressive NK cell Leukemia

Corresponding Author	How to Cite this Article	To Browse
Sabina Langer, Senior Consultant, Department of Laboratory Haematology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India. Email: sabinapost@yahoo.com	Goel D, Langer S, Kotwal J, Saraf A, Prakhar P, Persistent Thrombocytopenia Post Autologous Transplant In A Case Of Extra Nodal Nk Cell Lymphoma. Trop J Pathol Microbiol. 2024;10(2):14-19. Available From https://pathology.medresearch.in/index.php/jopm/article/view/634	

Manuscript Received 2024-01-01	Review Round 1 2024-01-02	Review Round 2 2024-01-08	Review Round 3 2024-01-14	Accepted 2024-01-20
Conflict of Interest Nil	Funding None	Ethical Approval Yes	Plagiarism X-checker 15.32	Note
 © 2024 by Goel D, Langer S, Kotwal J, Saraf A, Prakhar P and Published by Siddharth Health Research and Social Welfare Society. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/ unported [CC BY 4.0]. 				

Introduction

Natural killer (NK)/T-cell lymphomas (NKTCLs) fall under non-Hodgkin lymphomas which are mostly extra nodal, frequently of NK or (rare) T-cell origin, being closely related to the Epstein-Barr virus (EBV) [1].

The World Health Organization (WHO) classifies NKTCL into Extra nodal(nasal or non-nasal), aggressive NK cell leukemia and Chronic lymphoproliferative disorder of NK cells or NK-large granular lymphocytic leukaemia (NK-LGLL) as per WHO 5th edition[2].

Nasal type NKTCL, previously referred to as lethal midline granuloma or angiocentric T-cell lymphoma, involves the upper aero-digestive tract with the nasal cavity, nasopharynx, paranasal sinuses, tonsils or palate. Non-nasal NKTCLs frequently involve the skin, testis or gastrointestinal tract, but they can affect many other sites [3]. The disseminated type, as the name implies, can involve many organs, along with a concomitant leukemic phase [4].

We hereby present a case report of the relapsed case of extranodal NK-T cell lymphoma which had a rare presentation at relapse as a disseminated disease without any evidence at the primary site of origin or any solid organ confirmed by PET-Scan of the patient.

Case report

A 55-year-old gentleman presented with nasal stuffiness and blockage in the ENT department in November 2022 for which he underwent functional endoscopic sinus surgery and septoplasty. The tissue was sent for histopathological examination (Fig 1) which revealed **Extra nodal NK T Cell Lymphoma**. (CD2, CD3 and CD56 positive).




Fig -1. HPE – 10X(Dense infiltration of sino nasal mucosa by lymphocytes. Inset -40x. IHC (40X) A – CD3 B- CD56

A staging bone marrow study was done at that time which did not show signs of involvement by the lymphoma. EBV testing by PCR was positive and revealed 1,75000 copies. He fell under Lugano Stage III and CNS IPI -3. He was started on chemotherapy as per the P-GemOx protocol. He completed four cycles of chemotherapy on Jan 23. Post chemotherapy he also underwent Radiotherapy and received 44 Gy external beam radiotherapy by IGRT in 22 fractions in March 2023. He underwent an Autologous bone marrow transplant in June 2023. The protocol used was the BEAM protocol. (Carmustine, Cytarabine, Etoposide, Mephalan). Total peripheral blood stem cell dose 2.5×10^6 /kg. Post-transplant hospital stay was relatively uneventful with no major complications/infections with counts started improving on Day +10.

However, only two months after autologous stem cell bone marrow transplantation, he developed fever, vomiting, and abdominal pain in August. CBC revealed isolated thrombocytopenia which when reviewed by peripheral smear examination showed 70% abnormal lymphoid cells that were moderate to large, moderate N: C ratio, hyperchromatic nucleus, and prominent nucleoli with the majority of them showing azurophilic granules (LGLs) (Fig -2). Many of them have blastoid morphology along with marked thrombocytopenia. Bone marrow done a day later showed infiltration by abnormal lymphoid cells with similar cytomorphology. Sections from bone marrow biopsy variably cellular marrow spaces with an show cellularity of ~50-55% with diffuse infiltration of the marrow by abnormal lymphoid cells seen interstitially as well as in sheets and clusters. There was Grade 1 fibrosis.




Fig -2 (a Peripheral smear, b- Bone marrow)– Large granular lymphocytes with blastoid morphology. (c) Bone marrow biopsy - diffuse infiltration of the marrow by abnormal lymphoid cells

Flow cytometry was done from peripheral blood which showed a cluster of abnormal lymphoid cells which had bright CD45 and low to intermediate Side scatter.

On further gating and analysis of the suspected population, these cells were found to be positive for CD56, CD2, cyt CD3 and negative for sCD3, CD7, CD5, CD4, CD8, CD16 and CD57 suggestive of NK cells. These cells showed bright tight clustering on CD94, CD38 and HLA-DR (Fig-3) and hence a diagnosis of relapse of extranodal N K cell lymphoma in disseminated form was given. A PET Scan was repeated at this stage which did not reveal any nasal or non-nasal solid organ involvement, which was a relatively rare presentation of a rare lymphoma (Fig 4)

He was started with one cycle of the Msmile regimen (modification of the SMILE regimen with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide incorporating pegylated asparaginase). Post that he had developed cytopenias and soon succumbed to infections.




Fig -3: Flowcytometric plots of extranodal NK/T cell lymphoma/leukemia.





Figure -4. PET Scan – Comparison between at diagnosis and at relapse.

Discussion and Review of Literature

Natural killer (NK)/T-cell lymphomas (NKTCLs) come under the category of non-Hodgkin lymphoma which are frequently extranodal, most of them of the nasal type. As for its epidemiology, a higher incidence has been observed in Asia as compared with Europe (22 vs. 5%) with an average life expectancy of less than a year. NKTCL appears most frequently in patients over the age of 60 years. They are identified in 12% of lymphoma patients, 68% of them having the nasal type, 26% extra nasal type, and 6% aggressive or unclassifiable type [5].

Nasal-type lymphoma is frequently located in the upper aero-digestive tract: nasal cavity, nasopharynx, paranasal sinuses, tonsils, hypopharynx and larynx, being invariably associated with the Epstein-Barr virus (EBV). The immunohistochemistry profile features include CD3+, CD43+, CD45RO+, CD56+, EBV+, CD8+, Epstein-Barr virus-encoded small RNA-positive (EBER+), with positivity for cytotoxic granular proteins [6,7]. The extranodal pattern of involvement seems to be connected with the CD56 marker, which is the neural cell adhesion molecule (NCAM) possessing hemophilic connection properties. The neoplastic cells are thus redistributed to other sites and evolve as new malignancy sites [8]. The skin is the most common site for NKTCL dissemination [9].

The general manifestations of NKTCLs include signs and symptoms located mainly in the face and neck regions: facial pain, diplopia, visual impairment, eyeball protrusion, eyelid ptosis, pupil anomalies, nasal obstruction, refractory sinusitis, velo-palatal motor disturbances, cranial nerve neuropathies, intra-orbital and intrasinus masses. Other associations consist of respiratory failure and liver and spleen enlargement.

FOXP3+ regulatory T cell expression of tumour-infiltrating lymphocytes is related to the early stage and predicts a better prognosis. Negative prognostic markers include age > 60, extranasal disease, B symptoms, elevated beta 2 microglobulin, soluble IL2 > 600 U/ml, C reactive protein > 1 mg/dl, high levels of serum or plasma cell-free EBV DNA by quantitative PCR and Stage III / IV[9,10].

Patients with aggressive NK-cell leukaemia have more prominent hepatosplenomegaly and lack the skin lesions occasionally found with extranodal NK/T-cell lymphoma. Expression of CD16 also is helpful, because this marker is negative in extranodal NK/T-cell lymphoma[11].

The therapeutic approach to extranodal NK/T-cell lymphoma is based on several factors, such as the age of patients, the extent of the disease, potential toxicities, and survivorship.

Patients with nasal disease (stage I-II) may be treated with concurrent chemoradiotherapy (CRT) regimens such as DeVIC (dexamethasone, etoposide, ifosfamide, and carboplatin) with radiation therapy (RT), or VIPD (etoposide, ifosfamide, cisplatin, dexamethasone) with RT. Other regimens that may be considered include sequential CRT with modified SMILE [dexamethasone (steroid), methotrexate, ifosfamide, pegaspargase, and etoposide] with RT, and sandwich CRT with P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) with RT[12].

At the end of induction therapy, patients should undergo an evaluation with PET/CT scans, ear, nose, and throat examination, and EBV viral load to establish remission status as we have done in our case. Results from PET/CT scans are interpreted using the Deauville criteria [13].

Patients with nasal disease (stage I-II) with complete remission (disappearance of all disease) may be observed without further treatment. In contrast, those with partial remission are treated as refractory diseases. In patients with nasal disease (stage IV) or extra nasal disease (stage I-IV) and relapsed/refractory disease hematopoietic stem cell transplant may be considered.

Conclusion

Our case is unique in a presentation at relapse because it presented as cytopenias (anaemia and marked thrombocytopenia) with the presence of abnormal aggressive-looking large granular lymphocytes present in both peripheral blood and bone marrow, suggestive of spillover or disseminated form of extranodal NK cell lymphoma, however, PET Scan did not reveal increased FDG uptake in any solid organ even at

The primary site. Also, our case highlights the aggressive nature of the tumour as it relapsed in 4 months after standard chemotherapy followed by autogenic stem cell transplantation. Hence, our case underlines the importance of not only early morphological and flow cytometric diagnosis of this rare lymphoma but also the need for the development of newer drugs/immunotherapy to cure it.

References

1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. *CA Cancer J Clin.* 2016 Nov 12;66(6):443-459 [Crossref][PubMed][Google Scholar]
2. Alaggio, R. , Amador, C. , Anagnostopoulos, I. et al. *The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.* *Leukemia* 36, 1720–1748 (2022) [Crossref][PubMed][Google Scholar]
3. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R. , International Peripheral T-Cell Lymphoma Project. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. *Blood.* 2009 Apr 23;113(17):3931-7 [Crossref][PubMed][Google Scholar]
4. Kim SJ, Jung HA, Chuang SS, Hong H, Guo CC, Cao J, Hong XN, Suzuki R, Kang HJ, Won JH, Chng WJ, Kwong YL, Suh C, Song YQ, Zhu J, Tay K, Lim ST, Suzumiya J, Lin TY, Kim WS. , Asia Lymphoma Study Group. Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group. *J Hematol Oncol.* 2013 Nov 16;6:86 [Crossref][PubMed][Google Scholar]
5. Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, Kim SJ, Cabrera ME, Shustov AR, Chiattone CS, Horwitz SM, Dlouhy I, Spina M, Hitz F, Montoto S, Nagler A, Martinez V, De Souza CA, Fernandez-Alvarez R, Ballova V, Gabús R, Inghirami G, Federico M, Kim WS. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. *Lancet Haematol.* 2020 Apr;7(4):e284-e294 [Crossref][PubMed][Google Scholar]
6. Bhatt VR, Koirala B, Terjanian T. Extranodal natural killer/T cell lymphoma, nasal type presenting as a palatal perforation and naso-oral fistula. *BMJ case reports.* Mar . pii: bcr1120103511 [Crossref][PubMed][Google Scholar]
7. Gru AA, Haverkos BH, Freud AG, Hastings J, Nowacki NB, Barrionuevo C, Vigil CE, Rochford R, Natkunam Y, Baiocchi RA, Porcu P. The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. *Curr Hematol Malig Rep.* 2015 Dec;10(4):456-67 [Crossref][PubMed][Google Scholar]
8. Zheng S, Ouyang Q, Li G, Xu H, Jiang M, Cui D, et al. Primary intestinal NK/T cell lymphoma: a clinicopathologic study of 25 Chinese cases. *Arch Iran Med.* (2012) 15:36–42 [Crossref][PubMed][Google Scholar]
9. Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim DH, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, Kim WS. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. *Leuk Lymphoma.* 2009 May;50(5):757-63 [Crossref][PubMed][Google Scholar]
10. Ding JJ, Chen YL, Zhou SH, Zhao K. Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/T-cell lymphoma. *J Int Med Res.* 2018 Dec;46(12):4920-4929 [Crossref][PubMed][Google Scholar]

11. Jenny C. Hoffmann, Lauren S. Maeda, Robert S. Ohgami,13 - *Indolent and Aggressive Mature T-Cell and Natural Killer-Cell Lymphomas*, Editor(s): Mohamed Salama, Julie Teruya-Feldstein, Marina Kremyanskaya, *Atlas of Diagnostic Hematology*, Elsevier,2021, Pages 251-273, ISBN 9780323567381 [Crossref][PubMed][Google Scholar]
12. Ding JJ, Chen YL, Zhou SH, Zhao K. Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/T-cell lymphoma. *J Int Med Res*. 2018 Dec;46(12):4920-4929 [Crossref][PubMed][Google Scholar]
13. Wei W, Wu P, Li L, Zhang ZH. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. *Hematology*. 2017 Jul;22(6):320-329 [Crossref][PubMed][Google Scholar]
14. Wong KF, Chan JK, Cheung MM, So JC. Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. *Am J Clin Pathol*. 2001 Feb;115(2):266-70 [Crossref][PubMed][Google Scholar]
15. Jaffe ES, Nicolae A, Pittaluga S. Peripheral T-cell and NK-cell lymphomas in the WHO classification: Pearls and pitfalls. *Mod Pathol*. 2013;26 (Suppl 1):S71-S87. doi: 10.1038/modpathol.2012.181 [Crossref][PubMed][Google Scholar]
16. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. *Lancet*. 2018;371:945-957 [Crossref][PubMed][Google Scholar]